250 related articles for article (PubMed ID: 26193376)
1. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.
Doniņa S; Strēle I; Proboka G; Auziņš J; Alberts P; Jonsson B; Venskus D; Muceniece A
Melanoma Res; 2015 Oct; 25(5):421-6. PubMed ID: 26193376
[TBL] [Abstract][Full Text] [Related]
2. The advent of oncolytic virotherapy in oncology: The Rigvir® story.
Alberts P; Tilgase A; Rasa A; Bandere K; Venskus D
Eur J Pharmacol; 2018 Oct; 837():117-126. PubMed ID: 30179611
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports.
Alberts P; Olmane E; Brokāne L; Krastiņa Z; Romanovska M; Kupčs K; Isajevs S; Proboka G; Erdmanis R; Nazarovs J; Venskus D
APMIS; 2016 Oct; 124(10):896-904. PubMed ID: 27457663
[TBL] [Abstract][Full Text] [Related]
4. Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir.
Čēma I; Kleina R; Doniņa S; Isajevs S; Zablocka T; Rasa A; Alberts P
Perm J; 2022 Sep; 26(3):139-144. PubMed ID: 35950985
[TBL] [Abstract][Full Text] [Related]
5. A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report.
Sorokins V; Tilgase A; Olmane E; Isajevs S; Zablocka T; Rasa A; Alberts P
SAGE Open Med Case Rep; 2020; 8():2050313X20934978. PubMed ID: 32637110
[TBL] [Abstract][Full Text] [Related]
6. Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease.
Voit C; Kron M; Schwürzer-Voit M; Sterry W
J Dtsch Dermatol Ges; 2003 Feb; 1(2):120-5. PubMed ID: 16285179
[TBL] [Abstract][Full Text] [Related]
7. Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin
Tilgase A; Patetko L; Blāķe I; Ramata-Stunda A; Borodušķis M; Alberts P
J Cancer; 2018; 9(6):1033-1049. PubMed ID: 29581783
[No Abstract] [Full Text] [Related]
8. Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.
Lee AY; Droppelmann N; Panageas KS; Zhou Q; Ariyan CE; Brady MS; Chapman PB; Coit DG
Ann Surg Oncol; 2017 Apr; 24(4):939-946. PubMed ID: 27804026
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
[TBL] [Abstract][Full Text] [Related]
10. Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines.
Tilgase A; Grīne L; Blāķe I; Borodušķis M; Rasa A; Alberts P
BMC Res Notes; 2020 Apr; 13(1):222. PubMed ID: 32299493
[TBL] [Abstract][Full Text] [Related]
11. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
13. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).
Balch CM; Soong SJ; Murad TM; Ingalls AL; Maddox WA
Ann Surg; 1981 Mar; 193(3):377-88. PubMed ID: 7212800
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG; Marshall A; Nathan PD; Lorigan P; Gore M; Tahir S; Faust G; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Westwell S; Casasola R; Chao D; Maraveyas A; Patel PM; Ottensmeier CH; Farrugia D; Humphreys A; Eccles B; Young G; Barker EO; Harman C; Weiss M; Myers KA; Chhabra A; Rodwell SH; Dunn JA; Middleton MR; ; Nathan P; Lorigan P; Dziewulski P; Holikova S; Panwar U; Tahir S; Faust G; Thomas A; Corrie P; Sirohi B; Kelly C; Middleton M; Marples M; Danson S; Lester J; Marshall E; Ajaz M; Houston S; Board R; Eaton D; Waterston A; Nobes J; Loo S; Gray G; Stubbings H; Gore M; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Marsden J; Westwell S; Casasola R; Chao D; Maraveyas A; Marshall E; Patel P; Ottensmeier C; Farrugia D; Humphreys A; Eccles B; Dega R; Herbert C; Price C; Brunt M; Scott-Brown M; Hamilton J; Hayward RL; Smyth J; Woodings P; Nayak N; Burrows L; Wolstenholme V; Wagstaff J; Nicolson M; Wilson A; Barlow C; Scrase C; Podd T; Gonzalez M; Stewart J; Highley M; Wolstenholme V; Grumett S; Goodman A; Talbot T; Nathan K; Coltart R; Gee B; Gore M; Farrugia D; Martin-Clavijo A; Marsden J; Price C; Farrugia D; Nathan K; Coltart R; Nathan K; Coltart R
Ann Oncol; 2018 Aug; 29(8):1843-1852. PubMed ID: 30010756
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic Properties and Genome Analysis of Rigvir
Hietanen E; Koivu MKA; Susi P
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336934
[TBL] [Abstract][Full Text] [Related]
16. A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®.
Ismailov Z; Rasa A; Bandere K; Brokāne L; Tilgase A; Olmane E; Nazarovs J; Alberts P
Am J Case Rep; 2019 Jan; 20():48-52. PubMed ID: 30635548
[TBL] [Abstract][Full Text] [Related]
17. Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics.
Samlowski W; Silver MA; Hohlbauch A; Zhang S; Scherrer E; Fukunaga-Kalabis M; Krepler C; Jiang R
Future Oncol; 2022 Oct; 18(33):3755-3767. PubMed ID: 36346064
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV; Luke JJ; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Mohr P; Dummer R; Gershenwald JE; Yoon CH; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Ascierto PA;
Lancet Oncol; 2022 Nov; 23(11):1378-1388. PubMed ID: 36265502
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virus preclinical toxicology studies.
Rasa A; Alberts P
J Appl Toxicol; 2023 May; 43(5):620-648. PubMed ID: 36299168
[TBL] [Abstract][Full Text] [Related]
20. 4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 virus Rigvir administered intramuscularly with a 4-week recovery period.
Piwoni K; Jaeckel G; Rasa A; Alberts P
Toxicol Rep; 2021; 8():230-238. PubMed ID: 33537211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
